Timberlyne Therapeutics
Siyu Shi, MD, MBA, is a prominent figure in the biotech and healthcare sectors, currently engaged with Mountainfield Venture Partners in biotech company creation and serving as co-founder and Senior Director of Operations at Timberlyne Therapeutics. Prior experience includes roles in biotech venture capital at F-Prime Capital and research in AI applications for healthcare at the Stanford Artificial Intelligence Laboratory. Notably, Siyu Shi contributed to oncology research at Stanford Health Care, leading to multiple publications and presentations at international conferences. Previous engagements also include positions at Blackstone, C3 AI, and Sofinnova Partners, alongside research in biomaterials at the Massachusetts Institute of Technology. Siyu Shi holds an MD from Stanford University School of Medicine and an MBA from Stanford Graduate School of Business, complemented by a Master's in Epidemiology from Stanford and a Bachelor's in Chemistry from Rice University.
This person is not in any teams
This person is not in any offices
Timberlyne Therapeutics
Timberlyne Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of transformational therapies for autoimmune diseases. We are leveraging the extensive drug development expertise of our team to acquire best-in-class assets against compelling targets, and applying them to disease areas with significant unmet need. Timberlyne’s lead program, CM313, is an IgG1 monoclonal antibody with enhanced complement-dependent cytotoxicity that targets CD38. By targeting CD38, highly expressed on plasma cells, NK cells, and other immune cells, CM313 can modulate multiple arms of the immune system leading to both rapid and durable responses across a range of autoimmune diseases. CM313 has been tested in numerous disease states including Immune Thrombocytopenia, Systemic Lupus Erythematosus, and relapsed/refractory Multiple Myeloma. Timberlyne plans to develop CM313 across a broad range of autoimmune indications. Launched in 2024, Timberlyne has raised $180 million from leading life sciences investors.